Growth Metrics

Armata Pharmaceuticals (ARMP) Share-based Compensation (2016 - 2026)

Quarterly results put Share-based Compensation at $1.1 million for Q1 2026, up 37.64% from a year ago — trailing twelve months through Mar 2026 was $2.9 million (down 7.52% YoY), and the annual figure for FY2025 was $2.6 million, down 9.78%.

Armata Pharmaceuticals has reported Share-based Compensation over the past 14 years, most recently at $1.1 million for Q1 2026.

  • Share-based Compensation reached $1.1 million in Q1 2026 per ARMP's latest filing, up from $632000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.3 million in Q2 2024 and bottomed at -$373000.0 in Q3 2023.
  • Median Share-based Compensation over the past 5 years was $632000.0 (2025), compared with a mean of $624764.7.
  • The largest annual shift saw Share-based Compensation crashed 144.09% in 2023 before it surged 411.49% in 2024.
  • Over 5 years, Share-based Compensation stood at $817000.0 in 2022, then tumbled by 76.38% to $193000.0 in 2023, then skyrocketed by 83.42% to $354000.0 in 2024, then skyrocketed by 78.53% to $632000.0 in 2025, then soared by 70.09% to $1.1 million in 2026.
  • Business Quant data shows Share-based Compensation for ARMP at $1.1 million in Q1 2026, $632000.0 in Q4 2025, and $622000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 892,057.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 305,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 166.40 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 257.40 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 70.15 Mn
10 Armata Pharmaceuticals 301.92 Mn 297.17 Mn - 1.08 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.08 Mn
Mar 31, 2026 1.08 Mn
Dec 31, 2025 632,000.00
Dec 31, 2025 632,000.00
Sep 30, 2025 622,000.00
Sep 30, 2025 622,000.00
Jun 30, 2025 575,000.00
Jun 30, 2025 575,000.00
Mar 31, 2025 781,000.00
Mar 31, 2025 781,000.00
Dec 31, 2024 354,000.00
Dec 31, 2024 354,000.00
Sep 30, 2024 670,000.00
Sep 30, 2024 670,000.00
Jun 30, 2024 1.34 Mn
Jun 30, 2024 1.34 Mn
Mar 31, 2024 534,000.00
Mar 31, 2024 534,000.00
Dec 31, 2023 193,000.00
Dec 31, 2023 193,000.00
Sep 30, 2023 -373,000.00
Sep 30, 2023 -373,000.00
Jun 30, 2023 261,000.00
Jun 30, 2023 261,000.00
Mar 31, 2023 857,000.00
Mar 31, 2023 857,000.00
Dec 31, 2022 817,000.00
Dec 31, 2022 817,000.00
Sep 30, 2022 846,000.00
Sep 30, 2022 846,000.00
Jun 30, 2022 949,000.00
Jun 30, 2022 949,000.00
Mar 31, 2022 493,000.00
Mar 31, 2022 493,000.00
Dec 31, 2021 664,000.00
Dec 31, 2021 664,000.00
Sep 30, 2021 469,000.00
Sep 30, 2021 469,000.00
Jun 30, 2021 907,000.00
Jun 30, 2021 907,000.00
Mar 31, 2021 842,000.00
Mar 31, 2021 842,000.00
Dec 31, 2020 862,000.00
Dec 31, 2020 862,000.00
Sep 30, 2020 663,000.00
Sep 30, 2020 663,000.00
Jun 30, 2020 906,000.00
Jun 30, 2020 906,000.00
Mar 31, 2020 1.04 Mn
Mar 31, 2020 1.04 Mn
Dec 31, 2019 1.05 Mn
Dec 31, 2019 1.05 Mn
Sep 30, 2019 2.50 Mn
Sep 30, 2019 2.50 Mn
Jun 30, 2019 724,000.00
Jun 30, 2019 724,000.00
Mar 31, 2019 99,000.00
Mar 31, 2019 99,000.00
Dec 31, 2018 -1,000.00
Dec 31, 2018 -1,000.00
Sep 30, 2018 8,000.00
Sep 30, 2018 8,000.00
Jun 30, 2018 13,000.00
Jun 30, 2018 13,000.00
Mar 31, 2018 122,000.00
Mar 31, 2018 122,000.00
Dec 31, 2017 132,000.00
Dec 31, 2017 132,000.00
Sep 30, 2017 98,000.00
Sep 30, 2017 98,000.00
Jun 30, 2017 299,000.00
Jun 30, 2017 299,000.00
Mar 31, 2017 171,000.00
Mar 31, 2017 171,000.00
Dec 31, 2016 297,000.00
Dec 31, 2016 297,000.00
Sep 30, 2016 334,000.00
Sep 30, 2016 334,000.00
Jun 30, 2016 548,000.00
Jun 30, 2016 548,000.00